Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Neuropharmacology. 2011 May 27;61(4):778–788. doi: 10.1016/j.neuropharm.2011.05.024

Figure 5. Effects of pre-treatment and co-treatment with AM251 and AM630 on WIN-induced CGRP release.

Figure 5

(A) Pre-treatment with AM630 reduces WIN-evoked CGRP release, while co-treatment of TG neurons with AM630 and WIN increase overall CGRP release. (B) Pre-treatment with AM251 does not affect WIN-evoked CGRP release, while co-treatment of neurons with AM251 and WIN substantially decreases overall CGRP release. Concentrations of drugs (AM251, AM630 and WIN) are indicated. Pre-treatment times with AM251 and AM630 are 15 min. WIN treatment and co-treatment with AM251 or AM630 was also for 15 min. Wash times 2 min each with two changes of Hanks solution, n = 6; error bars = SEM **p<0.01, ***p<0.001. (C) Co-treatment of WIN with indicated concentrations of AM630 increase overall CGRP release in a concentration-dependent fashion. (D) In contrast, co-treatment of WIN with indicated concentrations of AM251 decrease overall CGRP release in a concentration-dependent fashion, n = 6; error bars = SEM, *p<0.05, **p<0.01. “B” indicates baseline release of CGRP.